Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cyto.2021.155544 http://scihub22266oqcxt.onion/10.1016/j.cyto.2021.155544 33926774!8052468!33926774     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cytokine 2021 ; 143 (ä): 155544 Nephropedia Template TP {{tp|p=33926774|t=2021. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19 |pdf=|usr=}}{{33926774}} gab.com Text Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19 JO: Cytokine http://www.kidney.de/pget.php?&tw=1&pmid=33926774 #FOAvip The overproduction of proinflammatory cytokines, resulting in what has been described as a cytokine storm or cytokine release syndrome (CRS), may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19) and is also a crucial cause of death from COVID-19. With the purpose of finding effective and low-toxicity drugs to mitigate CRS, IL-1 blockade agents, which are one of the safest ways to stop this overwhelming innate immune response, are already available in several preliminary reports or are under observational trials and may offer an important treatment option in hyperinflammatory COVID-19. In this review, we described the key information in both case reports and clinical studies on the potential beneficial features of IL-1 inhibitors in COVID-19 patients. Twit Text FOAVip Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19 ????Cytokine http://www.kidney.de/pget.php?&tw=1&pmid=33926774 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33926774 #FOAvip English Wikipedia <ref>{{Cite pmid|33926774}}</ref> Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19 #MMPMID33926774 Geng J; Wang F; Huang Z; Chen X; Wang Y Cytokine 2021[Jul]; 143 (ä): 155544 PMID33926774show ga The overproduction of proinflammatory cytokines, resulting in what has been described as a cytokine storm or cytokine release syndrome (CRS), may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19) and is also a crucial cause of death from COVID-19. With the purpose of finding effective and low-toxicity drugs to mitigate CRS, IL-1 blockade agents, which are one of the safest ways to stop this overwhelming innate immune response, are already available in several preliminary reports or are under observational trials and may offer an important treatment option in hyperinflammatory COVID-19. In this review, we described the key information in both case reports and clinical studies on the potential beneficial features of IL-1 inhibitors in COVID-19 patients. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |COVID-19/mortality/pathology[MESH] |Cytokine Release Syndrome/*drug therapy/pathology[MESH] |Female[MESH] |Humans[MESH] |Interleukin 1 Receptor Antagonist Protein/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Receptors, Interleukin-1 Type I/*antagonists & inhibitors[MESH] |Receptors, Interleukin-1/*antagonists & inhibitors[MESH] |Recombinant Fusion Proteins/therapeutic use[MESH]Perspectives on anti-IL-1 inhibitors as potential therapeutic interven(epmc).pdf DeepDyve Pubget Overpricing